Amgen Inc is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix and received approval for bone-strengthening drug Prolia/Xgeva.
| Website: | www.amgen.com |
| Email: | investor.relations@amgen.com |
| Main Phone: | +1 805 447-1000 |
| Address: | One Amgen Center Drive |
| Address 2: | Suite 2650 |
| State: | CA |
| City / Town: | Thousand Oaks |
| Country: | USA |
| Postal Code: | 91320-1799 |
| Exchange: | NGS |
| CEO: | Robert A. Bradway |
| Employees: | 20800 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
| Last Price 196.37 | Change $ -0.04 | Change % -0.02 | Tick N/A |
| Bid 196.37 | Bid Size 200.00 | Ask 196.46 | Ask Size 100.00 |
| Open 196.77 | High 197.59 | Low 195.22 | Prev Close 196.41 |
| Last Trade | Volume 1.2 mi | 52 Wk Hi 210.19 | 52 Wk Low 163.31 |
| Market Cap 125.1 bi | Ex-Div Date | Div Rate 5.80 | Yield 2.9530 |
| Shares 637,219,244.00 | EPS (TTM) 3.82 | PE Ratio 51.40 | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 45 | 74 |
| Number of Buys | 23 | 31 |
| Number of Sells | 22 | 43 |
| Net Activity | -8304 | 75103 |
| Last 10 Buys | Shares |
|---|---|
| Fred Hassan | 1,000 |
| Fred Hassan | 1,000 |
| Frank C. Herringer | 1,000 |
| Frank C. Herringer | 1,000 |
| Robert A. Bradway | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| De Francois Carbonnel | 1,000 |
| Sean Harper | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 224 | 224 | 224 | 224 |
| Low Target Price Estimate | 165 | 165 | 165 | 165 |
| Mean Target Price Estimate | 193.94 | 193.94 | 193.12 | 193.94 |
| Standard Deviation | 15.01 | 15.01 | 14.92 | 15.01 |
| Date of Most Recent Estimate | 06/03/18 | 05/22/18 | 05/22/18 | 06/03/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| CT ORDER | 1 | 2018-05-30 | |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-22 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-22 |
| CT ORDER | 1 | 2018-05-17 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 12 | 13 | 14 | 14 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.22 | 2.26 | 2.3 | 2.3 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
